SCHEDULE 13G: TCG Crossover Entities Disclose 5.7% Stake in Tyra Biosciences

TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu have jointly disclosed a beneficial ownership of 5.7% in Tyra Biosciences, Inc., totaling 2,898,103 shares of common stock.

Summary

• TCG Crossover Fund I, L.P., TCG Crossover GP I, LLC, and Chen Yu (collectively, the "Reporting Persons") have filed a Schedule 13G indicating beneficial ownership in Tyra Biosciences, Inc.
• The Reporting Persons collectively own 2,898,103 shares of Tyra Biosciences, Inc. Common Stock.
• This ownership represents 5.7% of the outstanding Common Stock of Tyra Biosciences, Inc.
• The percentage of ownership is calculated based on 50,602,991 shares of Common Stock outstanding, as reported in Tyra Biosciences' Form 10-Q filed on November 7, 2024.
• TCG Crossover GP I, LLC is the general partner of TCG Crossover Fund I, L.P., and Chen Yu is the sole managing member of TCG Crossover GP II, which is related to the general partner structure.
• All beneficially owned shares have shared voting and shared dispositive power among the Reporting Persons.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates a significant institutional investment in the company, suggesting investor confidence, but the document itself is a factual disclosure without explicit positive or negative commentary on company performance.

Positives

• A significant institutional investment group, TCG Crossover, has taken a substantial 5.7% stake in Tyra Biosciences, which can be viewed as a vote of confidence in the company's future prospects.

Risks

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G, which clarifies their individual filing obligations but does not preclude potential coordinated actions in the future.
• The beneficial ownership is determined based on the Issuer's previously reported shares outstanding, and any changes to this number could slightly alter the reported percentage.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Tyra Biosciences, Inc.'s future performance or strategic direction.

Industry Context

This filing indicates a significant investment by a crossover fund in a biotechnology company, which is a common investment strategy for funds looking to invest in both private and public companies within the life sciences sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor like TCG Crossover may be perceived positively, potentially signaling confidence in the company's value and prospects, which could influence investor sentiment.

Key Dates

Keywords

Tyra Biosciences, TCG Crossover, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, SEC Filing, Biotechnology, Investment Fund